Filing Flows › Comparisons › ZVRA vs VTVT
Zevra Therapeutics vs vTv Therapeutics: ZVRA and VTVT compared
Zevra Therapeutics is the larger company: $37.8M of revenue in its latest quarter (Q3 2026) against $36.8M for vTv Therapeutics (Q1 2026). vTv Therapeutics is more profitable, with an operating margin of 63.1% against 30.7%.
Where the money goes: ZVRA and VTVT
Zevra Therapeutics (ZVRA) · Q3 2026
Zevra Therapeutics, Q3 2026: revenue $37.8M (+45% year over year), operating margin 30.7%, net earnings $19.2M, operating cash flow $10.0M. The chart follows the revenue to costs, profit and cash.
vTv Therapeutics (VTVT) · Q1 2026
vTv Therapeutics, Q1 2026: revenue $36.8M, operating margin 63.1%, net earnings $24.1M, operating cash flow $9.2M. The chart follows the revenue to costs, profit and cash.
| Zevra Therapeutics (ZVRA) | vTv Therapeutics (VTVT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 2026 |
| Revenue | $37.8M | $36.8M |
| Revenue growth, Y/Y | +45% | — |
| Operating margin | 30.7% | 63.1% |
| Net earnings | $19.2M | $24.1M |
| Net margin | 50.9% | 65.5% |
| Operating cash flow | $10.0M | $9.2M |
| Free cash flow | $9.8M | — |
| Market value | $636M | — |
| P/E | 8.5× | — |
| Analysts’ mean target | $25.25 | — |
Questions
Which is bigger, Zevra Therapeutics or vTv Therapeutics?
Zevra Therapeutics is the larger company: $37.8M of revenue in its latest quarter (Q3 2026) against $36.8M for vTv Therapeutics (Q1 2026).
Is Zevra Therapeutics or vTv Therapeutics growing faster?
vTv Therapeutics is more profitable, with an operating margin of 63.1% against 30.7%.
More: Zevra Therapeutics earnings · how Zevra Therapeutics makes money · vTv Therapeutics earnings · how vTv Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed May 13, 2026). Fiscal quarters can end on different dates. Not investment advice.